Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

University of British Columbia

Headquarters: Vancouver, BC, Canada
Year Founded: 1908
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Jul 5, 2024
Product Development

LNP innovation: tissue specificity, aided by AI

How LNP companies delivering nucleic acids are cracking the tissue tropism problem, and finding freedom to operate
BioCentury | Mar 20, 2024
Emerging Company Profile

Reverb: redirecting endogenous cytokines to tumors

Vancouver-based Reverb is making bispecific antibodies to nab cytokines and deliver them to a desired cell or tissue
BioCentury | Dec 1, 2023
Discovery & Translation

CorrectSequence’s hemoglobin base editor; plus Denali’s LXR agonist and more

BioCentury’s roundup of translational innovations
BioCentury | May 17, 2023
Emerging Company Profile

Nido Bio: treating neurodegeneration with small molecules

Debuting with $109M, 5AM Ventures-backed company developing small molecule corrector of a genetic neuromuscular disease
BioCentury | Mar 29, 2023
Discovery & Translation

Inhibiting desmosomal protein degradation in cardiomyopathy; plus senescence data from AKL and more

BioCentury’s roundup of translational news
BioCentury | Mar 16, 2023
Data Byte

Translational spotlight on variant-proofing tech for COVID and beyond

Host targets and antiviral strategies with efficacy across multiple viruses in BioCentury’s Distillery
BioCentury | Aug 26, 2022
Discovery & Translation

Detecting Parkinson’s via breathing signals; plus Antisense, Noster and more

BioCentury’s roundup of translational news
BioCentury | May 2, 2022
Distillery Therapeutics

A TMPRSS2 inhibitor for SARS-CoV-2

BioCentury | Feb 1, 2022
Deals

Jan. 31 Quick Takes: After top-line NASH data, Madrigal looks ahead to biopsy readout

Plus Moderna, Novavax, Gandeeva, Cytovation, Takeda
Items per page:
1 - 10 of 215